DBV Technologies Announces 3-Year Results From EPITOPE Phase 3 Open-Label Extension Study; Data Provided Support That Continued Treatment With VIASKIN Peanut Showed Improveemntn Through 36 Months Of Treatment Across All Efficacy Parameters

DBV Technologies宣佈EPITOPE第三階段開放標籤擴展研究的三年結果；數據提供了支持，顯示持續使用VIASKIN花生治療的患者在各項療效參數上經過36個月的治療後有明顯改善。

Benzinga · 01/09 05:08

EPITOPE OLE data demonstrates continued improvement in treatment benefit of VIASKIN Peanut patch in toddlers 1 – 3 years through 36 months
68.2% of subjects completed the oral food challenge (~12-14 peanut kernels) without meeting stopping criteria, compared to 30.7% at month 12
No treatment-related anaphylaxis or serious treatment-related Treatment-Emergent Adverse Events (TEAEs) occurred in year three of EPITOPE OLE
DBV also announced daily patch wear time data from EPITOPE that is supportive of the Company's proposed labeling approach shared with FDA
DBV to highlight these data in multiple abstract presentations at the Eastern Food Allergy & Comorbidity Conference, January 9-12, in Palm Beach, Florida
- Company to host investor webcast today at 5:00pm ET

EPITOPE OLE數據顯示，VIASKIN花生貼片對1至3歲幼兒的治療效益在36個月內持續改善。
68.2%的受試者在口服食物挑戰中完成（約12-14顆花生）而未達到停止標準，12個月時爲30.7%
在EPITOPE OLE的第三年中，沒有發生與治療相關的過敏反應或嚴重的治療相關不良事件（TEAE）
DBV還公佈了EPITOPE每日貼片佩戴時間的數據，支持公司與FDA分享的提議標籤方案。
DBV將在2025年1月9日至12日在佛羅里達州棕櫚灘舉行的東部食品過敏與共病會議上，通過多個摘要展示這些數據。
- 公司將在今日東部時間下午5:00舉辦投資者網絡研討會

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。更多信息

風險及免責聲明